تحميل...

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

BACKGROUND: Interleukin-17A (IL-17A) antagonists are a recent innovation for treating psoriatic arthritis (PsA). There are currently no cost-effectiveness analyses (CEAs) comparing the IL-17A antagonists ixekizumab and secukinumab in PsA from a UK perspective. OBJECTIVE: We conducted a CEA from the...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Pharmacoecon Open
المؤلفون الرئيسيون:	Schweikert, Bernd, Malmberg, Chiara, Åkerborg, Örjan, Kumar, Gayathri, Nott, Debby, Kiri, Sandeep, Sapin, Christophe, Hartz, Susanne
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Springer International Publishing 2020
الموضوعات:	Original Research Article
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7688884/ https://ncbi.nlm.nih.gov/pubmed/32166657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-020-00202-1
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

مواد مشابهة